28 May 2019
Visiongain has launched a new pharma report Checkpoint Inhibitors for Anti-Cancer Treatment Market Report: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs.
Checkpoint inhibitors have changed the landscape of melanoma treatment in the last few years and advanced it in ways that could not have been possible before. The response rates achieved and survival rates are so much higher than any seen before and metastatic melanoma patients are living much longer. The global checkpoint inhibitor for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.
The lead analyst of the report commented "One opportunity for driving growth in the checkpoint inhibitor market is the development of companion diagnostic tests. These tests would be indispensable as they would allow treatment to be given only to those patients who would derive the most benefit from it and not add to the cost burden by eliminating patients who would gain no advantage from using this treatment or would be susceptible to severe side effects such as autoimmune-related effects."
Leading companies featured in the report include AstraZeneca, Plc, Bristol-Myers Squibb Co., Celldex Therapeutics, Inc., Incyte Corporation, Merck & Co., Inc, Novartis, Pfizer, Roche and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.
19 October 2020
The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.
12 October 2020
We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
02 October 2020
The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.